In squamous cell carcinoma, the levels of nitric oxide (NO) derived from inducible NO synthase (iNOS) and prostaglandin E 2 (PGE 2 ) derived from cyclooxygenase-2 (COX-2) originated from tumor cells or tumor-associated inflammatory cells have been reported to correlate with tumor growth, metastasis, and angiogenesis. The present study examined the role of the iNOS signaling pathway in PGE 2 -mediated tumor invasiveness and proliferation in squamous cell carcinoma, A431, and SCC-9 cells. Cell invasion and proliferation promoted by PGE 2 were blocked by iNOS silencing RNA or iNOS/guanylate cyclase (GC) pharmacological inhibition. Consistently, iNOS-GC pathway inhibitors blocked mitogen-activated protein kinase-ERK1/2 phosphorylation, which was required to mediate PGE 2 functions. In vivo, in A431 cells implanted in nude mice, GC inhibition also decreased the tumor proliferation index and ERK1/2 activation. PGE 2 effects were confined to the selective stimulation of the EP2 receptor subtype, leading to epidermal growth factor receptor (EGFR) transactivation via protein kinase A (PKA) and c-Src activation. EP2-mediated ERK1/2 activation and cell functions were abolished by inhibitors of PKA, c-Src, and EGFR, as well as by inhibiting iNOS pathway. Silencing of iNOS also impaired EGFR-induced ERK1/2 phosphorylation. These results indicate that iNOS/GC signaling is a downstream player in the control of EP2/EGFR-mediated tumor cell proliferation and invasion.-Donnini, S., Finetti, F., Solito, R., Terzuoli, E., Sacchetti, A., Morbidelli, L., Patrignani, P., Ziche, M. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J. 21, 2418 -2430 (2007) 
turn, angiogenesis (i.e., the increased formation of new vessels) is perhaps the most important determinant of tumor growth and metastasis spread (2) . In a previous report investigating head and neck cancer patients, we have shown that microvessel density of the tumor periphery, and particularly the invasive edge of the tumor, strongly correlated with the increased expression of inducible nitric oxide synthase (iNOS) protein and iNOS activity (3) . The notion that iNOS is a key player in tumor development, widely documented for a variety of solid tumors, is now a mainstay of cancer biology (3) (4) (5) (6) . Recent reports have emphasized the importance of inducible cyclooxygenase (COX-2) and its products for the progression of a variety of tumors including prostate and colon, head and neck, ovarian tumors, and hepatocellular carcinoma (7) (8) (9) (10) (11) (12) . Overexpression of COX-2 has been documented to be associated with invasive metastatic process, resulting in a poor prognosis for cancer patients (13) . There is also clear evidence for a close interplay between iNOS and COX-2 proteins that extends to their respective products, nitric oxide (NO) and the prostanoid prostaglandin E 2 , PGE 2 (14 -16) . Thus, the COX-2 overexpression observed in tumors may be viewed as part of the concerted process leading to increased angiogenesis and metastatic spread (17) . Most tumors that intensely express COX-2 enzyme have also been found to contain high levels of PGE 2 (18, 19) . PGE 2 exerts its autocrine/paracrine effects on target cells by coupling to four subtypes of G-protein-coupled receptors classified as EP1, EP2, EP3, and EP4 (E-series prostanoid receptors) (20, 21) . These receptors are often coexpressed in the same cell type and use different, and in some cases, opposing intracellular signaling pathways (22) (23) (24) (25) (26) . Studies reported the crucial role played in particular by EP2 or EP4 receptor signaling in mediating tumor progression and/or tumor-associated angiogenesis (27) (28) (29) . Recently, it was shown that PGE 2 stimulation of both EP2 and EP4 receptors involves transactivation of the epidermal growth factor receptor (EGFR) signaling pathway to promote tumorigenesis (30 -32) . EGFR phosphorylation leads to activation of downstream signaling molecules involved in cell proliferation and survival pathways of the ras/raf/MAPK and PI3K/Akt, respectively (33) (34) (35) .
In squamous cell carcinoma, overexpression of EGFR has been correlated with increased levels of COX-2 and iNOS activity, PGE 2 and NO production, angiogenesis, and metastasis; this in turn has been correlated with a poor prognosis and resistance to therapy (2, 36, 37) . To date, a direct cross-linking between iNOS, COX-2/ PGE 2 , and EGFR has not been elucidated.
In the present study the squamous carcinoma cells, A431 and SCC-9, were used to delineate the role of iNOS/guanylate cyclase (GC) signaling pathway on prostanoid-mediated stimulation of tumor cell invasion and growth. Moreover, in PGE 2 -mediated A431 cell invasion and growth, the role of MAPK-ERK1/2 was investigated, and the potential link between iNOS/GC signaling and ERK1/2 activity was elucidated.
Results indicate that PGE 2 -induced promotion of A431 tumor invasion and growth requires activated iNOS-CG and MAPK-ERK1/2, and is mediated by EGFR transactivation via EP2/PKA and the c-Src signaling pathway.
MATERIALS AND METHODS

Cell lines
Human epidermoid carcinoma A431 and SCC-9 cells were obtained by ATCC (Manassas, VA, USA). Cells were maintained in culture in DMEM (A431) or in F12:DMEM (SCC-9) supplemented with 4500 mg/L glucose, 2 mM l-glutamine, antibiotics (100 U/ml penicillin and 100 g/ml streptomycin) and 10% fetal calf serum (FCS) (Hyclone, Logan, UT, USA). All media and antibiotics for cell culture were purchased from Sigma (St. Louis, MO, USA). Cells were split 1:8 (A431) or 1:5 (SCC-9) twice a week.
Cell proliferation assay
Cell proliferation was quantified by Vybrant MTT cell proliferation assay kit (Molecular Probes, Carlsbad, CA, USA). A431 cells (2.5ϫ10 3 ) or SCC-9 (3ϫ10 3 ) were seeded in 96-multiwell plates in medium with 10% serum for 18 h, starved in 0.1% FCS for 24 h, then exposed to PGE 2 (Sigma), NOC-12 (Calbiochem-Novabiochem, La Jolla, CA, USA), or PGE 2 receptor subtype agonists (17-phenyl trinor prostaglandin E-2, Butaprost, sulprostone, and prostaglandin E-1 alcohol, obtained from Cayman Chemicals, Ann Arbor, MI, USA) for 48 h in 0.1% FCS. Where indicated, cells were pretreated with NOS pathway inhibitors l-nitro-M-methyl arginine, l-NMMA (Sigma), and 1H-(1, 2, 4)oxadiazolo [4,3-a] quinoxalin-1-one, ODQ (Alexis Biochemicals, Lausen, Switzerland) or the PKA inhibitor H89 (Calbiochem-Novabiochem), the MEK inhibitor U0126 (Calbiochem-Novabiochem), or the EGFR inhibitor AG1478 (Calbiochem-Novabiochem) for 40 min in 0.1% FCS, then stimulated with PGE 2 , NOC-12, or the EP agonists. After 44 h, medium was removed and cells were incubated for 4 h with fresh medium in the presence of 1.2 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Living cells reduce MTT to a strongly pigmented formazan product. After solubilization in DMSO, absorbance of the formazan was measured with a microplate absorbance reader (Tecan, San Jose, CA, USA) at 540 nm. Data are reported as 540 nm absorbance/well.
Invasion assay
Cell invasion was investigated using the modified Boyden chamber as described previously with minor modifications (38) . Briefly, 3 ϫ 10 5 cells were seeded in a 6 cm dish in 10% FCS for 18 h, starved in 0.1% for 24 h, then trypsinized and stimulated for 40 min with or without the NOS pathway inhibitors or PKA, MEK, or EGFR inhibitors in 0.1% FCS. Cell suspension (1.2ϫ10 4 cells) was added to the upper wells. PGE 2 or NOC-12 was used as chemoattractive molecules. Invasion was measured in triplicate by counting the number of cells that had moved in 16 h across the filter coated with Matrigel (250 g/ml). Cells were counted in five random fields/well at a magnification of 400ϫ. Data are reported as total number of cells counted/well.
Western blot analysis
The procedure was performed as described previously (39, 40) . Electrophoresis was carried out in SDS/10% polyacrylamide gels for iNOS, ERK1/2, and EP receptors and in SDS/8% polyacrylamide gels for phospho-tyrosine, EGFR, or anti-PKA C-␣. Membranes were incubated for 18 h at 4°C with mouse monoclonal primary antibody directed against iNOS (Cayman Chemicals, Ann Arbor, MI, USA), human phospho-ERK1/2 (Cell Signaling Technology, Inc., Danvers, MA, USA), rabbit anti-EP receptors (anti-EP1, EP2, and EP3 Cayman Chemicals, USA; anti-EP4 was kindly provided by Drs. M. D. Breyer and R. M. Breyer, Vanderbilt University Medical School, Nashville, TN, USA), antiphospho-tyrosine (P-Tyr-100) (Cell Signaling Technology), or anti-EGFR or anti-PKA C-␣ (Cell Signaling Technology, Inc.), diluted 1:2000 (anti-P-ERK1/2 and anti-PKA C-␣) and 1:1000 (anti-EP receptors, anti-P-Tyr, anti-EGFR, and anti-iNOS) in PBS. The primary antibody was detected by incubating the membranes for 1 h with horseradish peroxidase-HRP conjugated rabbit anti-mouse secondary antibody (Promega, Madison, WI, USA) or goat anti-rabbit (Sigma) diluted 1:2000, and 1:2500, respectively, in PBS, followed by enhanced chemiluminescence system for detection (Amersham, Arlington Heights, IL, USA). Images were digitalized with CHEMI DOC Quantity One program, blots were analyzed in duplicate by densitometry using NIH Image 1.60B5 software, and the optical density (OD) values were normalized to OD for total EGFR (phospho-tyrosine blots), total ERK1/2 (phospho-ERK1/2 blots), or actin (EP receptors and iNOS).
siRNA transfection
21-Nucleotide RNAs were chemically synthesized by Qiagen (Milan, Italy). Synthetic oligonucleotides were deprotected and gel-purified as described (41) . The siRNA sequence targeting human iNOS (5Ј-AACCCAGCTGCTGCTCCAAAA-3Ј) corresponded to region 2661-2681 relative to the start codon, and targeting human PKACA (5Ј-AAGCCGGAGAATCTGCT-CATT-3Ј) corresponded to region 704 -724 relative to the start codon. Control siRNA is a random siRNA provided by Qiagen (Valencia, CA, USA). For annealing of siRNAs, 20 M single strands were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, and 2 mM magnesium acetate) for 1 min at 90°C followed by 1 h at 37°C. The day before transfection, cells were trypsinized and 3 ϫ 10 5 cells were seeded in 6-well plates. Transient transfection of siRNA was carried out using lipofectamine (Invitrogen, Carlsbad, CA, USA). OPTIMEM medium (100 l) (Life Technologies, Inc., Gaithersburg, MD, USA) and 10 l lipofectamine per well were preincubated for 5 min at room temperature. During the period for this incubation, 100 l OPTIMEM medium was mixed with 10 g siRNA. The two mixtures were combined and incubated for 20 min at room temperature for complex formation. After incubation, the entire mixture was added to the cells in a final concentration of 300 nM siRNAs. Cells were assayed 48 h after transfection.
Immunohistochemistry
After transfection with siRNA for iNOS, the cells were washed in PBS, fixed in acetone at Ϫ20°C, and washed again extensively. After blocking unspecific binding sites in 3% bovine serum albumin (BSA), the cells were incubated overnight at 4°C with the monoclonal antibody anti-iNOS (BD Transduction Laboratories, San Jose, CA, USA) diluted 1:30 in PBS containing 0.5% BSA. After the primary antibody, the cells were washed and incubated for 2 h with an isothiocyanatelabeled goat anti-mouse IgG secondary antibody (Sigma) diluted 1:50 in PBS with 0.5% BSA and mounted in Moviol 4 -88 (Calbiochem).
NOS activity
NOS activity was measured as described previously (42) . Briefly, 5 ϫ 10 5 A431 cells in 60 mm culture dishes were stimulated for 4 h with 50 g/ml LPS, 1 M PGE 2 , or 10 ng/ml EGF and treated as described (3) . All determinations were performed in duplicate. NOS activity is expressed as picomoles of [ 3 H]citrulline formed/min per mg protein (pmol/min per mg proteins).
In vivo studies
Experiments have been performed in accordance with the guidelines of the European Economic Community for animal care and welfare (EEC Law No. 86/609) and the National Ethical Committee. To assess the in vivo effect of NOS pathway inhibition on A431 tumor growth, female immunodeficient mice (5-to 8-wk-old CD-1 nude mice, Charles River, Wilmington, MA, USA) were s.c. inoculated in the right flank with 10 7 A431 cells in a volume of 50 l. After 10 days, when tumors reached a volume of 300 mm 3 , animals were randomly assigned to two different experimental protocols (5 mice per group). At this time peritumor treatment (i.e., injection of the ODQ, 10 M/day/ mice) or vehicle (5% DMSO in PBS) close to the tumor mass began. Daily treatment was performed for 4 consecutive days. Animals were observed daily for signs of cytotoxicity and sacrificed by CO 2 asphyxiation. At day 5 animals were sacrificed and each tumor was split into two parts: one part was immediately frozen in liquid nitrogen for measurement of cGMP content; the other part was embedded in Tissue-Tek O.C.T. (Sakura, San Marcos, CA, USA), cooled in isopentane, and frozen in liquid nitrogen for histology. cGMP levels were measured in tissue homogenates by radioimmunoassay as described (3) . Seven mthick cryostat sections from tissue samples were stained with hematoxylin and eosin, and adjacent sections were used for immunohistochemical staining with the anti-COX-2 (Cayman), anti-microsomial prostaglandin E synthase-1 (m-PGES-1) (Cayman), anti-EP2 receptor (Cayman), anti-Ki67 (Chemicon, Temecula, CA, USA), and antiphospho-ERK1/2 (Cell Signaling) antibodies. Cryostat sections were first fixed in acetone Ϫ20°C and incubated for 10 min in 3% H 2 O 2, washed (3ϫ5 min) in TBS, then incubated in a blocking reagent (KIT Immunoperoxidase Secondary Detection System, Chemicon). Primary antibodies were then applied as follows: mouse monoclonal antiKi67 diluted 1:100 in PBS, 0.05% BSA; mouse monoclonal anti-COX-2, diluted1:100 (5 g/ml) in PBS, 0.05% BSA; rabbit polyclonal anti-m-PGES-1 diluted 1:100 (5 g/ml) in TBS, 0.05% BSA; mouse monoclonal anti-EP2 diluted 1:100 in TBS, 0.05% BSA, mouse monoclonal anti-pERK diluted 1:100 in TBS, 0.05% BSA. All the antibodies were applied for 1 h at room temperature. Sections were then washed (3ϫ5 min in TBS) and incubated for 10 min in the appropriate species-specific biotinylated secondary antibodies (goat anti-mouse and goat anti-rabbit IgG, KIT Immunoperoxidase Secondary Detection System, Chemicon). After washing (3ϫ5 min in TBS), the sections were incubated for 10 min in streptavidin-conjugated HRP. After this incubation, sections were exposed to 3,3-diaminobenzidine tetrahydrocloride for 8 min to produce a brown reaction product. Sections were then counterstained in hematoxylin and mounted in Aquatex (Merck, Rahway, NJ, USA). Western blot analysis for phosphotyrosine and EGFR was performed as reported above (see Western blot analysis).
Statistical analysis
Results are expressed as means Ϯ se. Statistical analysis was performed using Student's t test and analysis of variance (ANOVA). When a significant difference was detected, multiple comparison analysis was performed using the StudentNewman-Keuls test. A value of P Ͻ 0.05 was considered to denote statistical significance.
RESULTS
PGE 2 promotes invasion and proliferation of squamous cell carcinoma via ERK1/2 activation
Squamous cell carcinoma responds to exogenous stimuli by increasing the synthesis of PGE 2 (36) . We wanted to study whether this mediator would change functional parameters such as invasiveness and growth in A431 and SCC-9 cells, models of squamous cell carcinoma. PGE 2 promoted cell invasiveness and growth in a concentration-related manner, maximal stimulation being obtained at 100 nM (Table 1) . Further, we investigated the role of ERK1/2, a signal typically involved in cell growth, in PGE 2 -induced invasiveness and proliferation of squamous cell carcinoma. PGE 2 (l M, 10 min stimulation) strongly enhanced ERK1/2 phosphorylation, a signal that was reduced by U0126 (10 M), the specific MEK inhibitor (Fig. 1A, B) . U0126 also suppressed invasion and proliferation of A431 and SCC-9 promoted by PGE 2 (Fig. 1C-F) , demonstrating that ERK1/2 activation mediates PGE 2 cellular functions.
PGE 2 transactivation of EGFR mediates squamous cell carcinoma growth and invasion
Since PGE 2 effects on tumor progression have been demonstrated to be mediated by transactivation of the EGFR (30 -32), we investigated whether PGE 2 was able to promote EGFR transactivation in squamous cell carcinoma and whether it was the obligatory step in mediating the PGE 2 responses. We assessed EGFR phosphorylation and cellular functions promoted by PGE 2 in the presence or absence of AG1478, the selective EGFR tyrosine kinase inhibitor. EGFR tyrosine phosphorylation was significantly increased by PGE 2 (l M, 5 min stimulation, Fig. 2A) . Consistently, EGFR phosphorylation was sensitive to AG1478, leading to suppression of PGE 2 -mediated cell growth ( Fig. 2A, B) . Similar results were obtained for invasion (data not shown).
EP2/PKA/c-Src pathway mediates EGFR transactivation and the cellular effects of PGE 2 Next, we investigated whether the transactivation of EGFR by PGE 2 could be assigned to a specific EP receptor subtype. First, we verified the presence of receptor subtypes in the squamous cell carcinoma model. Western blotting revealed the constitutive presence of EP1, EP2, EP3, and EP4 receptors in A431 cells (Fig. 3A) and in SCC-9 cells (data not shown). EGFR tyrosine phosphorylation was assessed after exposure of cells to each subtype selective agonist (17-phenyl trinor prostaglandin for EP1/EP3, Butaprost for EP2, sulprostone for EP3, prostaglandin E-1 alcohol for EP4), all at 1 M for 5 min. Since only EP2 stimulation with (Fig. 3B) . Consistently, AG1478 suppressed transactivation of EGFR (Fig. 3C) .
Since PKA has been reported to mediate PGE 2 intracellular signaling after activation of EP2 receptor subtype (21), we investigated its role in PGE 2 /EP2-mediated EGFR transactivation as well as in PGE 2 cell functions. Incubation with H89 (500 nM), a PKA blocker (43, 44) , abolished both PGE 2 and Butaprostpromoted EGFR phosphorylation (Fig. 3C, D) , reduced PGE 2 -induced ERK1/2 phosphorylation, and affected functional parameters in an A431 tumor cell line (Fig.  4A, B) . Similar results were obtained with SCC-9 (data not shown). To confirm the requirement of PKA activation for EGFR phosphorylation, we also silenced PKA activity by siRNA technology. Reduction of PKA expression in A431 significantly inhibited PGE 2 -induced EGFR phosphorylation, leaving EGF activity unchanged (Fig. 5A) . Similar results were obtained for SCC-9. These results indicate that EGFR transactivation is required for the full expression of PGE 2 actions in these cells.
In addition, EGFR pathway stimulation appeared to be dependent on c-Src activity, as application of its inhibitor (PP1, 500 nM) abolished PGE 2 -promoted phosphorylation of EGFR (Fig. 5B) .
The results clearly suggest that PGE 2 -mediated transactivation of EGFR is both PKA and c-Src dependent. 
iNOS/GC signaling mediates PGE 2 cellular and molecular effects in squamous cell carcinoma
As squamous cell carcinoma growth and invasion promoted by PGE 2 appear to be regulated through EGFR transactivation and because in these tumors overexpression of EGFR and COX-2 has been correlated with increased levels of iNOS activity, we examined whether there was interplay between these signals. First, we analyzed the modulation of iNOS signaling pathway by measuring functional effects of PGE 2 (1 M) in A431 cells after iNOS silencing by siRNA technology (Fig. 6A, B) . Silencing of iNOS inhibited both basal cGMP production by 40% (data not shown), and suppressed PGE 2 -induced invasion and proliferation (Fig. 6C, D) . Transfection with the siRNA control did not change PGE 2 -induced functions (Fig. 6C, D) . Pharmacological inhibitors of the iNOS-GC pathway (l-NMMA, 200 M, or the GC inhibitor ODQ,10 M) also inhibited PGE 2 -induced growth and invasion, as well as ERK1/2 activity, leaving control responses intact (Fig. 6E-G) . These results emphasize the requirement of a functional iNOS/GC signaling for the expression of PGE 2 effects in squamous cell carcinoma.
The involvement of iNOS/GC signaling in transducing EP2/PGE 2 effects was also documented by studying the effect of Butaprost (1 M), which promoted growth, invasion, and ERK1/2 activation in A431 tumor cells (Fig. 7A-C) . These responses were suppressed by pretreatment with AG1478 (1 M), U0126 (10 M), or NOS/GC signaling pathway inhibitors (Fig. 7A, B) as well as by si-iNOS mRNA (Fig. 7C) . These data underscore the relevance of iNOS/GC signaling in EP2/PGE 2 -mediated functions via EGFR transactivation. 
iNOS activity regulates PGE 2 /EGF/EGFR signal transduction system in A431 cells
On the basis of the above evidence showing that PGE 2 transactivates EGFR and activates iNOS/GC intracellular signaling, we investigated the role of iNOS signaling in the EGFR cascade in A431 cells. Exposure to PGE 2 (1 M for 18 h) markedly stimulated iNOS activity (4-fold, PϽ0.01) whereas inhibition of PKA or Src activity significantly decreased it (Fig. 8A) , demonstrating that iNOS controls PGE 2 effects through PKA and Src. EGF (10 ng/ml) increased NO levels Ͼ5-fold (PϽ0.01) while blockade of EGFR through AG1478 (1 M) suppressed both PGE 2 and EGF-induced NOS activity (Fig. 8A) . Moreover, silencing iNOS expression by si-iNOS mRNA reduced EGF-induced growth and invasion as well as ERK1/2 activation (Fig. 8B-D) , providing clear evidence that in squamous cell carcinoma the signaling activated by PGE 2 /EGFR transactivation impinges on the iNOS pathway to execute its functional effects.
iNOS/GC pathway lies upstream to ERK1/2 activity and proliferation in growing A431 tumors
To evaluate whether the observed signaling events triggered by PGE 2 via iNOS/GC pathway in vitro (i.e., ERK1/2 activity and proliferation) would operate in A431 cells grown as a tumor mass in vivo, A431 tumors were produced in nude mice. Immunohistochemical analyses showed the capability of tumor mass to produce and respond to prostanoids, since COX-2, m-PGES-1, and EP2 receptors were markedly expressed (Fig. 9A-C) . Moreover, tumor mass showed high levels of iNOS, suggesting the presence of elevated intratumoral levels of NO (Fig. 9D) .
When tumors were well established (10 days), nude mice were treated with the GC inhibitor ODQ, and the proliferative index and ERK1/2 phosphorylation were measured (day 14) in the tumor mass. Peritumoral treatment with ODQ (10 M/day/mice) reduced cGMP production compared with the control group (2.97Ϯ1.4 vs. 6.3Ϯ1.1 fmol/mg protein). In ODQ-treated mice, the proliferative index, measured by Ki-67 marker, and ERK1/2 phosphorylation were selectively reduced in the epithelial components of the tumor mass relative to controls (Fig.  9E-H) . We then examined whether ODQ treatment would modify EGFR activity in these tumors. Immunoprecipitation of EGFR and subsequent phosphotyrosine Western blot analysis indicated that EGFR existed in an activated state and was unaffected by cGMP inhibition (Fig. 9G) . Thus, consistent with the in vitro observations, in growing A431 tumors the iNOS/GC signaling pathway is upstream to ERK1/2 activity and affects the proliferative status of tumor cell population, whereas it lies downstream to EGFR signaling. 
DISCUSSION
PGE 2 and EGF independently propagate through their respective membrane receptors, signals inducing the proliferation of a wide variety of epithelial tumors (7, 8, (45) (46) . However, growing evidence indicates that the epithelial tumorigenic drive is largely sustained by the close interplay of the prostanoid with the EGF system, resulting in the transactivation of EGFR. In this study we examined the influence of the tumor-generated NO on the PGE 2 /EGFR intracellular signaling in squamous tumor cells, A431 and SCC-9, providing evidence that the NOS/GC pathway leads to downstream activation of ERK1/2 activation, cell invasiveness, and growth. The first clue for the NO relevance originates from the observation of enhanced iNOS activity in cultured tumor cells after their exposure to PGE 2 or EGF. Another indication comes from the iNOS silencing experiments (either siRNA technology or pharmacological inhibitors), which strongly reduced the PGE 2 -promoted stimulation of intracellular signals (ERK1/2 phosphorylation) and tumorigenic activity (growth and invasiveness). Although not investigated in this study, downstream of GC, a mediator for MAPK signaling pathway activation, may be the protein kinase cGMPdependent (PKG) observed earlier by us and others in different cell types (47-49) (see Fig. 10 ). In analogy with the cultured tumor cells, the iNOS pathway appears to be activated in vivo on proliferating epithelial tumor cells, A431, as its blockade by ODQ treatment severely curtails their proliferative activity (measured by the Ki-67) or ERK1/2 phosphorylation. The in vivo condition shown in this study illustrates the presence of the PGE 2 /EGFR/NOS-GC interaction paradigm. In fact, we found high expression levels of iNOS, COX-2, and m-PGES-1, suggesting the presence of elevated levels of PGE 2 and NO in tumors and of both EP2 receptor subtype and phosphorylated EGFR, which are suggestive of their potential functional role in tumor progression.
The issue of PGE 2 /EGFR transactivation (i.e., whether the prostanoid conveys its tumorigenic potential by promoting the phosphorylation of the EGFR) appears straightforward, at least for A431 and SCC-9, the epithelial tumor cells examined in this study. The phenomenon of EGFR tyrosine kinase transactivation by prostanoid G-protein-coupled receptors (GPCR) has been described for transducing mitogenic signals and tumor growth, suggesting that multiple intracellular signal pathways can be coactivated after prostanoidreceptor binding (30 -32, 37, 50, 51) . On the other hand, PGE 2 has also been reported to promote tumor cell growth in an EGFR-independent manner (52). These different signal transduction pathways induced by PGE 2 seem to depend on the type of tumor cells under study and on the subtype of GPCR involved in the signaling (28, 30, 53) . In squamous cell carcinoma, PGE 2 , upon binding to its receptor subtype EP2, initiates a cascade of events involving both PKA and cSrc, which culminates with the phosphorylation of EGFR. Previous reports have also described the transactivation of EGFR mediated by EP2 receptor in human Ishikawa endometrial adenocarcinoma cells or EP4 receptor in human colorectal cells (31, 32, 54) . PGE 2 -mediated effects on tumor and host cells depend on the expression of four different EP receptors (EP1-EP4), providing intracellular signaling by different mechanisms [e.g., increase of Ca 2ϩ and inositol levels (EP1), elevation of cAMP (EP2/EP4), activation of PI3K-Akt signal transduction pathway (EP4), or reduction of cAMP synthesis (EP3)] (20) . Although A431 cells express all four receptor subtypes (EP1 through EP4), only the EP2 subtype appears to be exclusively endowed with the ability to transduce the PGE 2 signal, since its selective stimulation via Butaprost stimulates ERK1/2 phosphorylation, cell invasiveness, and growth, all of which are sensitive to EGFR inhibition. As a corollary to the PGE 2 /EP2-promoted transactivation of EGFR, analysis of signals such as PKA and c-Src (31, 32, 54) provides insight into their role on the mechanism of EGFR transactivation in squamous carcinoma cells. In fact, the evidence obtained in cultured cells with the specific inhibitors of cSrc or PKA, PP1, and H89, respectively (for the latter, also by silencing its mRNA) (55), provides compelling evidence that these intermediate molecules are necessary for EGFR activation. Moreover, these inhibitors as well as the blockade of EGFR phos- phorylation by AG1478 obliterate the PGE 2 tumorpromoting activity as well as iNOS activity. Silencing of iNOS also suppresses EGF-induced ERK1/2 activation and tumor cell growth and invasion, providing clear evidence that iNOS signal transduction pathway is a molecular mechanism required for the PGE 2 /EP2-EGFR-induced postreceptor effects in A431 cells. These results do not exclude the possibility that PGE 2 may directly activate iNOS without EGFR. For example, the prostanoid may activate Akt by stimulating the EP4 subtype receptor, which induces phosphorylation of iNOS (56, 57) .
In conclusion, the principal finding of this study is that, in squamous carcinoma cell lines A431 and SCC-9, iNOS is the dominant downstream player in the control of PGE 2 -induced growth and invasion, being instrumental for the prevailing tumorigenic drive (i.e., the EGF-EGFR system). In other epithelial tumors, such as NSCLC, PGE 2 exerts its tumor growth potential independently from the EGF-EGFR system (51) . On the other hand, the role of NOS as a crucial intermediate in the progression of squamous carcinomas finds a clinical correlate in head and neck cancer, in which specimens taken from patients have been described to express high levels of NOS, which correlated strongly with tumor aggressiveness (3) .
The recognition that iNOS/GC signaling works in concert with the stromal-derived PGE 2 and the EGF protumorigenic pathway reinforces the key role exerted by NOS in inflammation and cancer, and the link between the two pathologies. The enrichment of inflammatory cells in the microenvironment around tumors provides an optimal milieu for cell proliferation, invasion, and angiogenesis, thereby favoring tumor development. In this study we found that, in tumor cells, the PGE 2 /EP2 receptor system transactivates EGFR via PKA and c-Src activation. The iNOS/CG signaling pathway regulates the downstream molecular/cellular effects of PGE 2 -activated-EGFR, such as ERK1/2 phosphorylation, tumor cell invasion, and proliferation. In the scheme, the potential direct activation of iNOS by PGE 2 /EP4/Akt signaling pathway is also illustrated. AC, adenylate cyclase; PKA, protein kinase A; GC, guanylate cyclase; PKG, protein kinase G.
